Therapeutic interventions in preterm infants are determined based on birth weight. Phototherapy (PTx) is the treatment for hyperbilirubinemia, started based on serum bilirubin level. However, weight-based guidelines for PTx in preterm infants are lacking. We present a simple way of calculating the bilirubin to initiate PTx. A percentage body weight, ranging from 0.5%-1%, is used to calculate bilirubin.
INTRODUCTION
Hyperbilirubinemia is a common problem in neonates. Phototherapy (PTx) is used to treat hyperbilrubinemia. The initiation of PTx depends upon the serum bilirubin level, clock hours counted from the time of birth and gestational age. Higher bilirubin level at early hours of life with low gestation is a strong indication of starting PTx. The dose of PTx is calculated as irradiance ranging between 15-40 µW/cm 2 /nm.
Established guidelines are available for PTx treatment for neonates older than 35 weeks [1] but data is scarce about the guidelines in preterm infants younger than 35 weeks [2] . In preterm infants, weight rather than gestational age is used for certain calculations and therapeutic interventions. Therefore, there is a need for a weight-based guideline for PTx. We present a simple weight-based approach to the initiation of PTx in preterm infants.
METHODS
We used the percent body weight as a factor determining the need for phototherapy. Total body water (TBW) of a preterm neonate is about 80% of the bodyweight (TBW = weight in grams x 0.80); 50% is extracellular and 30% is intracellular. Plasma/serum constitutes about 5% of the TBW. With the change in gestation and weight, body fluid composition changes. A serum bilirubin level of 5 mg/dL in a 500-gram infant is different than a 1500-gram infant. Using the principle of TBW and determining changes in the body fluid composition, we developed a weight-based guide for PTx in preterm infants. For infants < 750 grams, we used 1% of body weight, 0.75% for 751-1500 grams and 0.5% for 1501-2500 grams (Box 1, 2 and 3) , respectively.
The study was a preliminary work depicting a mathematical formula for initiating PTx. No sample size calculation was performed. For comparison with other methods of initiating PTx in preterm infants, we used data published by Maisels et al. [2] . We compared our weight-based approach with their data. Table 1 depicts the findings. For each gestation, we selected the corresponding mean weight using the Fenton chart for boys. We used the boys' chart for uniformity. As noted in Table 1 , for gestational age less than 28 weeks, the phototherapy level of bilirubin level ranges from 5-6 mg/dL. Based on Fenton's chart, < 28 weeks correspond to 500-1100 grams mean weight. By using percent body weight formula (1% for < 750 and 0.75% for 750-1500 grams), the bilirubin was found to be in the range of 5-8 mg/dL. A similar trend was noted with increasing gestational age.
RESULTS

DISCUSSION
Phototherapy could be associated with potential complications in preterm infants including transepidermal water loss, rash and possibly seizures. The approach to the treatment of hyperbilirubinemia with PTx could be conservative or aggressive depending on the ranges of TSB used [3] . When we compared our approach to the Norwegian guidelines [4], we noted our approach to be conservative ( Table 2) . The mean bilirubin level for all weight ranges matches the calculated bilirubin.
The tool used in our brief report is available at zero cost. It is a simple mathematical tool based on infant's birth weight. Based on this study, we planned an IRB follow-up study on real patients comparing the outcomes of reducing serum bilirubin level using the mathematical tool and guidelines described recently [5 -8] . 
CONCLUSION
In conclusion, the weight-based approach, by using percent body weight as a factor, to initiate phototherapy in preterm infants is a simple way of managing hyperbilirubinemia. Further studies should be done to investigate the validation of this approach.
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